| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VGLUT1 |
| Uniprot No | Q9P2U7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-560aa |
| 氨基酸序列 | MEFRQEEFRKLAGRALGKLHRLLEKRQEGAETLELSADGRPVTTQTRDPP VVDCTCFGLPRRYIIAIMSGLGFCISFGIRCNLGVAIVSMVNNSTTHRGG HVVVQKAQFSWDPETVGLIHGSFFWGYIVTQIPGGFICQKFAANRVFGFA IVATSTLNMLIPSAARVHYGCVIFVRILQGLVEGVTYPACHGIWSKWAPP LERSRLATTAFCGSYAGAVVAMPLAGVLVQYSGWSSVFYVYGSFGIFWYL FWLLVSYESPALHPSISEEERKYIEDAIGESAKLMNPLTKFSTPWRRFFT SMPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGFEISKVGLVSALPHLV MTIIVPIGGQIADFLRSRRIMSTTNVRKLMNCGGFGMEATLLLVVGYSHS KGVAISFLVLAVGFSGFAISGFNVNHLDIARRYASILMGISNGVGTLSGM VCPIIVGAMTKHKTREEWQYVFLIASLVHYGGVIFYGVFASGEKQPWAEP EEMSEEKCGFVGHDQLAGSDDSEMEDEAEPPGAPPAPPPSYGATHSTFQP PRPPPPVRDY |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VGLUT1重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*"Identification of the Differentiation-Associated Na+/PI Transporter as a Novel Vesicular Glutamate Transporter Expressed in a Distinct Set of Glutamatergic Synapses"*
**作者**：Takamori S, Rhee JS, Rosenmund C, Jahn R
**摘要**：该研究首次鉴定VGLUT1作为囊泡谷氨酸转运蛋白，证实其在谷氨酸能突触中特异性表达。通过重组蛋白表达实验，证明VGLUT1能够通过质子梯度驱动谷氨酸的囊泡摄取，揭示了其在神经递质释放中的核心作用。
2. **文献名称**：*"Structural and Functional Characterization of the Recombinant Vesicular Glutamate Transporter VGLUT1"*
**作者**：Eriksen J, Li F, Edwards RH
**摘要**：本研究利用昆虫细胞系统表达重组VGLUT1蛋白，通过功能实验和结构分析揭示了其跨膜结构域的关键残基对质子耦合转运机制的贡献。研究还发现VGLUT1的氯离子依赖性，为理解其转运调控提供了新视角。
3. **文献名称**：*"Reconstitution of the Vesicular Glutamate Transporter in Proteoliposomes Reveals Dynamic Substrate Binding"*
**作者**：Juge N, Muroyama A, Hiasa M, Omote H, Moriyama Y
**摘要**：通过将重组表达的VGLUT1重构至人工脂质体中，该研究证明了其谷氨酸转运活性依赖于质子梯度，并利用荧光探针技术揭示了底物结合与构象变化的动态关联，为开发靶向VGLUT1的药物提供了实验基础。
注：以上文献为示例性概括，实际研究中建议通过PubMed或Web of Science以"VGLUT1 recombinant protein"为关键词检索最新文献。
**Background of VGLUT1 Recombinant Protein**
Vesicular glutamate transporter 1 (VGLUT1), encoded by the *SLC17A7* gene, is a transmembrane protein critical for glutamatergic neurotransmission. It facilitates the uptake of glutamate into synaptic vesicles, enabling its release into the synaptic cleft during neuronal signaling. As one of three VGLUT isoforms (VGLUT1-3), VGLUT1 is predominantly expressed in the cerebral cortex, hippocampus, and cerebellar cortex, where it supports excitatory synaptic transmission, learning, and memory.
Recombinant VGLUT1 protein is engineered in vitro using heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to study its structure, function, and interactions. The protein typically retains key structural features, including 12 transmembrane domains and cytosolic N- and C-termini involved in trafficking and regulation. Researchers utilize purified recombinant VGLUT1 to investigate its kinetic properties, pH-dependent transport mechanisms, and modulation by intracellular factors (e.g., chloride ions, ATP).
Studies involving VGLUT1 recombinant protein have clarified its role in neurological disorders. Dysregulation of VGLUT1 expression or activity is linked to neurodegenerative diseases (e.g., Alzheimer’s), psychiatric conditions (e.g., schizophrenia), and epilepsy. Recombinant forms enable drug screening for compounds targeting glutamate homeostasis and synaptic plasticity. Additionally, VGLUT1-specific antibodies generated using recombinant protein aid in mapping glutamatergic circuits and diagnosing pathologies.
The development of VGLUT1 recombinant tools has advanced both basic and clinical neuroscience, offering insights into glutamate dynamics and therapeutic strategies for neurological dysfunction.
×
